Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dichlorphenamide
Drug ID BADD_D00652
Description A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Indications and Usage For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
Marketing Status approved; investigational
ATC Code S01EC02
DrugBank ID DB01144
KEGG ID D00518
MeSH ID D004005
PubChem ID 3038
TTD Drug ID D0J4GO
NDC Product Code 72065-002; 59651-223; 13668-676; 71090-001; 73435-011; 72065-001; 58159-071
UNII VVJ6673MHY
Synonyms Dichlorphenamide | Dichlofenamide | Diclofenamid | Glauconide | Daranide
Chemical Information
Molecular Formula C6H6Cl2N2O4S2
CAS Registry Number 120-97-8
SMILES C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urine abnormality20.02.01.0130.000899%-
Vertigo04.04.01.003; 17.02.12.0020.001176%
Vision blurred06.02.06.007; 17.17.01.0100.000646%
Visual impairment06.02.10.0130.000703%-
Vocal cord paralysis17.04.06.002; 22.04.01.0020.000254%
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.0080.000254%-
Peripheral swelling02.05.04.015; 08.01.03.0530.001234%-
Muscle fatigue15.05.03.0060.000392%-
Muscle tightness15.05.03.0070.000588%-
Balance disorder08.01.03.081; 17.02.02.0070.001234%-
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.0120.000588%-
Hyperphosphaturia14.04.03.006; 20.02.01.025---
Ear discomfort04.03.01.0050.000450%-
Paranasal sinus discomfort22.12.03.0180.000392%-
Musculoskeletal stiffness15.03.05.0270.001626%-
Growth retardation05.03.02.007; 14.03.02.031; 15.03.05.0160.000115%
Affect lability19.04.01.0010.000450%-
Cerebral disorder17.02.10.0170.000254%-
Urine phosphorus increased13.11.01.047---
Paraesthesia oral07.05.05.035; 17.02.06.0080.001038%-
Cognitive disorder17.03.03.003; 19.21.02.0010.001430%
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.0050.000646%
Cardiac disorder02.11.01.0030.000703%-
Limb discomfort15.03.04.0140.000784%-
Mental disorder19.07.01.0020.000254%-
Motor dysfunction15.05.06.006; 17.01.02.0310.000507%-
Decreased appetite08.01.09.028; 14.03.01.0050.002467%
Disease recurrence08.01.03.0500.012255%-
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages